https://pharmoniq.com/news/bristol-myers-squibb-portfolio-transformation-patent-cliff-2024 PharmoniQ en 2026-06-13T14:10:49.109Z Bristol Myers Squibb Tackles Portfolio Shift Amid Patent Expirations Bristol Myers Squibb, patent cliff, pharmaceutical portfolio, drug development, biosimilars https://pharmoniq.com/news/unapproved-peptides-regulatory-gaps-2024 PharmoniQ en 2026-06-13T08:47:03.106Z Unapproved Peptides Flood Market Amid Regulatory Oversight Gaps peptides, FDA regulation, unapproved drugs, compounding pharmacies, drug enforcement https://pharmoniq.com/news/fda-ai-drug-development-timeline-reduction PharmoniQ en 2026-06-12T14:10:49.112Z FDA Targets 45% Cut in Drug Development Time with AI Integration FDA, artificial intelligence, drug approval, clinical trials, regulatory innovation